Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Prostate Cancer – Current Treatment – Current Treatment: Physician Insights – Prostate Cancer (US)
Hormonal therapy remains the foundation of drug treatment for prostate cancer across all patient populations, with ADT serving as the universal backbone. ARPIs—enzalutamide, apalutamide, and…
Squamous Cell Carcinoma of the Head and Neck – Current Treatment – Current Treatment: Physician Insights – Squamous Cell Carcinoma of the Head and Neck (US)
The treatment of non-nasopharyngeal SCCHN is heterogeneous and guided by multiple factors, such as tumor burden and growth, the line of therapy, and prior treatment exposure. In the locoregionally…
Squamous Cell Carcinoma of the Head and Neck – Current Treatment – Treatment Sequencing – Squamous Cell Carcinoma of the Head and Neck (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Breast Cancer – Current Treatment – Current Treatment: Physician Insights – Breast Cancer (US)
The breast cancer treatment landscape is rapidly evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) combined with endocrine therapy, are established…
Hepatocellular Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The hepatocellular carcinoma therapy market is experiencing substantial growth. Angiogenesis inhibitors have played a central role in treating advanced disease, and immunotherapies such as Roche’…
